¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"HIV clinical trials."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIV
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • clinical
    Áø·á-, ÀÓ»ó-
  • clinical algorithm
    ÀÓ»óÀû¾Ë°í¸®µë
  • clinical chart
    º´·ÂÁö
  • clinical crib
    1. ÀÓ»ó¿ëÀ¯¾ÆÄ§´ë 2. ÀÓ»ó¿ë°Ý»ó±³Á¤ÀåÄ¡
  • clinical crown
    ÀÓ»óÄ¡¾Æ¸Ó¸®, ÀÓ»óÄ¡¾Æ°ü
  • clinical cytogenetics
    Àӻ󼼯÷À¯ÀüÇÐ
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clinical dementia rating scale
    ÀÓ»óÄ¡¸ÅÆò°¡Ã´µµ
  • clinical diagnosis
    ÀÓ»óÁø´Ü
  • clinical efficacy
    ÀÓ»óÈ¿´É
  • clinical epidemiologist
    ÀÓ»ó¿ªÇÐÀÚ
  • clinical epidemiology
    ÀÓ»ó¿ªÇÐ
  • clinical finding
    ÀÓ»ó¼Ò°ß
  • clinical laboratory
    ÀÓ»ó°Ë»ç½Ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIV
    (¢¡human immunodeficiency virus) »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • clinical
    Áø·á-. ÀÓ»ó-
  • objective structured clinical (OSCE) examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
  • clinical manifestation
    ÀÓ»óÁõ»ó, ÀÓ»ó¼Ò°ß
  • clinical trial
    ÀÓ»ó½ÃÇè
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • clinical algorithm
    ÀÓ»óÀû³í¸®Ã¼°è
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clinical
    ÀÓ»ó-
  • clinical chart
    º´»óÀÏÁö
  • clinical crib
    ÀÓ»ó¿ëÀ¯¾ÆÄ§´ë, ÀÓ»ó¿ë°Ý»ó±³Á¤ÀåÄ¡
  • clinical crown
    ÀÓ»óÄ¡¾Æ¸Ó¸®, ÀÓ»óÄ¡¾Æ°ü
  • clinical data
    ÀÓ»óÀÚ·á
  • clinical diagnosis
    ÀÓ»óÁø´Ü
  • clinical efficacy
    ÀÓ»óÈ¿´É
  • clinical epidemiologist
    ÀÓ»ó¿ªÇÐÀÚ
  • clinical epidemiology
    ÀÓ»ó¿ªÇÐ
  • clinical finding
    ÀÓ»ó¼Ò°ß
  • clinical laboratory
    ÀÓ»ó°Ë»ç½Ç
  • clinical manifestation
    ÀÓ»óÁõ»ó, ÀÓ»ó¼Ò°ß
  • clinical material
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Clinical data
    ÀÓ»óÀÚ·á
  • Clinical skills
    ÀÓ»ó¼ú±â
  • GCP : good clinical practice
    ÀÓ»ó½ÃÇè °ü¸®±âÁØ.
  • Good Clinical Practice(GCP)
    ÀǾàǰ ÀÓ»ó½ÃÇè °ü¸®±âÁØ
  • SCAG, Sandoz Clinical Assessment-Geriatric
    »êµµ½º ³ëÀÎÀÓ»óÆò°¡(-ôµµ)
  • SCAN, Schedule for Clinical Assessment in Neuropsychaitry
    ½Å°æÁ¤½Å°ú¿¡ ÀÖ¾î ÀÓ»óÆò°¡¸¦ À§ÇÑ ¸ñ·Ï
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • HIV => human immunodeficiency virus
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • HIV effect
    HIV È¿°ú<ÀÛ¿ë>
  • HIV infection
    HIV °¨¿°
  • HIV infection diagnosis
    HIV °¨¿°Áø´Ü
  • HIV testing
    HIV °Ë»ç
  • HIV-1
    Á¦1Çü »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • HIV-2
    Á¦2Çü »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hiv(human immunodeficiency virus)
    ÀÎü¸é¿ª°áÇ̹ÙÀÌ·¯½º(ìÑô÷Øóæ¹ÌÀù¹¡­)
  • human immunodeficiency virus=HIV
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus (HIV)
    »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • human immunodeficiency virus (HIV) infection
    »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º °¨¿°
  • human immunodeficiency virus = HIV
    Àΰ£ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus(HIV)
    »ç¶÷ ¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • bacteriology, clinical
    ÀÓ»ó¼¼±ÕÇÐ
  • clinical application
    ÀÓ»óÀûÀÀ¿ë<--Àû¿ë>
  • clinical bacteriology
    ÀÓ»ó¼¼±ÕÇÐ
  • clinical chart
    º´»óÀÏÁö.
  • clinical clerk
    ÀÓ»ó¼­±â(ÊÙË×Ë»).
  • clinical correlation
    ÀÓ»óÀû »ó°ü°ü°è
  • clinical crib
    ÀÓ»ó¿ë À¯¾ÆÄ§´ë(¡­éÄêêä®öÖÓæ).
  • clinical crown
    ÀÓ»óÄ¡¾Æ°ü, ÀÓ»óÄ¡°ü(ìúßÉöÍή).
  • clinical crown
    ÀÓ»óÄ¡¾Æ¸Ó¸®
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Clinical crown
    ÀÓ»óÄ¡¾Æ¸Ó¸®
    [¿¾ ¿ë¾î] ÀÓ»óÄ¡°ü
  • Clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
    [¿¾ ¿ë¾î] ÀÓ»óÄ¡±Ù
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • clinical parasitology
    ÀÓ»ó±â»ýÃæÇÐ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIV
    (å²) human immunodeficiency virus
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • clinical application
    ÀÓ»óÀû¿ë
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AIDSDRUGS clinical trials of acquired immunodeficiency drugs [MEDLARS data base]
AIDSTRIALS clinical trials of acquired immunodeficiency syndrome drugs [MEDLARS data base]
CTN calcitonin; clinical trials notification; computer tomography number; continuous noise
CTS carpal tunnel syndrome; clinical trials support [program]; composite treatment score; computed tomog...
CTTAC clinical trials and treatment advisory committee
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACTG AIDS Clinical Trials Group
CCTs Controlled clinical trials
PACTG Paediatric AIDS Clinical Trials Group
RCT Randomized controlled clinical trials
HIV AN HIV associated nephropathy
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 26735
    JournalTitle: HIV clinical trials.
    MedAbbr: HIV Clin Trials
    ISSN: 1528-4336
    ESSN:
    IsoAbbr:
    NlmId: 100936377
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute HIV infection syndrome
    ±Þ¼º ÀÎü ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º Áúȯ °¨¿° ÁõÈıº
  • HIV
    Àΰ£ ¸é¿ª ¾ïÁ¦ ¹ÙÀÌ·¯½º
    Human Immunodeficiency VirusÀÇ Áظ». ÈÄõ¼º ¸é¿ª °áÇÌÁõ
  • HIV antibody
    HIV Ç×ü
  • HIV associated periodontal disease
    HIV¿Í °ü·ÃµÈ Ä¡ÁÖ Áúȯ
  • HIV disease
    ÀÎü ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º Áúȯ
  • clinical application
    ÀÓ»óÀû Àû¿ë
  • clinical chart
    º´»ó ÀÏÁö
  • clinical cytogenetics
    ¼¼Æ÷ À¯ÀüÇÐ
    À¯Àü, Áï ¿°»öü¿Í °ü°èµÈ ¼¼Æ÷ ¿ä¼Ò¸¦ ¿¬±¸ÇÏ´Â À¯ÀüÇÐÀÇ ºÐ¾ß.
  • clinical diagnosis
    ÀÓ»ó Áø´Ü, ÀÓ»óÀû Áø´Ü
    Áø´ÜÀº º¸Åë º´·ÂÀ» ûÃëÇÏ°í ½ÅüÀû ¼Ò°ßÀ» ÃëÇϸç Çʿ信 µû¶ó¼­ °Ë»çÇÏ°í ¾òÀº Á¤º¸¸¦ Á¾ÇÕÇØ¼­ ³»·ÁÁö´Â °ÍÀ¸·Î ÀÌ¿Í °°Àº Áø´ÜÀ» ¼ö¼ú ½Ã¿¡ È®ÀÎÇÑ ¼ö¼ú½Ã Áø´Ü, ¶Ç´Â »çÈÄ ºÎ°Ë¿¡ ÀÇÇØ¼­ È®ÀÎµÈ º´¸® Áø´ÜÀ» ´ëºñ½ÃÄѼ­ ÀÓ»ó Áø´ÜÀ̶ó°í ÇÑ´Ù.
  • clinical examination
    ÀÓ»ó °Ë»ç, ÀÓ»ó ÁøÂû, ÀÓ»óÀû °üÂû
  • clinical hematology
    ÀÓ»ó Ç÷¾×ÇÐ
  • clinical interview
    ÀÓ»ó ¸é´ã
  • clinical locking
    ÀÓ»óÀû °úµÎ °É¸²
  • clinical material
    ÀÓ»ó °¡°Ë¹°, ÀÓ»ó °Ëü
  • clinical modification code
    ÀÓ»ó ¼öÁ¤ ºÎÈ£
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
clinical research trials Evaluating the safety and effectiveness of medications or medical devices by monitoring their effects on large groups of people. Clinical medical trials sponsored by the U. S. Government are listed on a web site of the National Institutes of Health (NIH). The NIH Clinical Centre intends to make details of current clinical research studies for various diseases available over the Internet to increase opportunities for patients and physicians to participate in clinical investigations.
(12 Dec 1998)
clinical trials Medical research studies conducted with volunteers. Each study is designed to answer scientific questions and to find better ways to prevent, detect, or treat cancer.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
controlled clinical trials Clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterised as randomised controlled trials. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are simply designated as controlled clinical trials.
(12 Dec 1998)
randomised controlled trials Clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and trials employing any of these techniques for patient assignment are designated simply controlled clinical trials.
(12 Dec 1998)
anti-HIV agents Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids.
(12 Dec 1998)
receptors, HIV Cellular receptors that bind the human immunodeficiency virus that causes aids. Included are CD4 antigens, found on t4 lymphocytes, and monocytes/macrophages, which bind to the HIV envelope protein gp120.
(12 Dec 1998)
chronic symptomatic HIV infection This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening.
Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss.
This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc).
(27 Sep 1997)
middle stage HIV disease <disease> This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening.
Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc).
(27 Sep 1997)
primary HIV infection <infectious disease> The flu-like syndrome that oc immediately after a person contracts HIV. This mini infection precedes seroconversion and is characterised fever, sore throat, headache, skin rash and swollen glands.
(06 Mar 1998)
HIV <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified.
Type 1: the retrovirus recognised as the agent that induces AIDS.
Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa.
Acronym: HIV
(11 Nov 1997)
HIV-1 The type species of lentivirus and widely recognised as the aetiologic agent of acquired immunodeficiency syndrome (aids). It is characterised by its cytopathic effect and affinity for the t4-lymphocyte.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIV
    human immunodeficiency virus;»ç¶÷ ¸é¿ª°áÇÌ ¹ÙÀÌ·¯½º;AIDS ¹ÙÀÌ·¯½º
  • Nuremberg trials
    ´µ¸¥º£¸£Å© ÀçÆÇ(³ªÄ¡½º Àü¹ü¿¡ ´ëÇÑ(1945-46))
  • clinical
    ÀÓ»óÀÇ
  • clinical
    ÀÓ»óÀÇ;º´»óÀÇ;º´½Ç¿ëÀÇ;(ÆÇ´Ü.¹¦»çµîÀÌ ±Øµµ·Î)°´°üÀûÀÎ;ºÐ¼®ÀûÀÎ;³ÃÁ¤ÇÑ;º´»ó(ÀÓÁ¾)ÀÇ (¼¼·Ê);~ly ÀÓ»óÀûÀ¸·Î
  • clinical death
    ÀÓ»ó»ç(±â±â¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í ÀÓ»óÀû °üÂû·Î ÆÇ´ÜÇÑ Á×À½)
  • clinical ecologist
    ÀÓ»ó »ýÅÂÇÐÀÚ
  • clinical ecology
    ÀÓ»ó »ýÅÂÇÐ
  • clinical pathology
    ÀÓ»ó º´¸®ÇÐ
  • clinical pharmacology
    ÀÓ»ó ¾àÇÐ
  • clinical psychology
    ÀÓ»ó ½É¸®ÇÐ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á